{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:15:35Z","timestamp":1793812535329,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01593-7","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T07:02:26Z","timestamp":1729321346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study"],"prefix":"10.1186","volume":"16","author":[{"given":"Karl","family":"G\u00f6tze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Vrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dumurgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Indart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sanchez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hela","family":"Slimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Raynaud-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cognat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Martinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hourr\u00e8gue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Bouaziz-Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Lilamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"1593_CR1","doi-asserted-by":"publisher","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius \u00c5 et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med CCLM [Internet]. 2016 [cited 2021 Mar 24];54. https:\/\/www.degruyter.com\/document\/doi\/https:\/\/doi.org\/10.1515\/cclm-2015-1195\/html","DOI":"10.1515\/cclm-2015-1195\/html"},{"key":"1593_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neulet.2017.04.027","volume":"650","author":"W Zhou","year":"2017","unstructured":"Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y, et al. Plasma neurofilament light chain levels in Alzheimer\u2019s disease. Neurosci Lett. 2017;650:60\u20134.","journal-title":"Neurosci Lett"},{"key":"1593_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. For the Alzheimer\u2019s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer Disease. JAMA Neurol. 2017;74:557.","journal-title":"JAMA Neurol"},{"key":"1593_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25:277\u201383.","journal-title":"Nat Med"},{"key":"1593_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of Disease Progression in Mouse models and in neurodegenerative diseases. Neuron. 2016;91:56\u201366.","journal-title":"Neuron"},{"key":"1593_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","volume":"10","author":"P Lewczuk","year":"2018","unstructured":"Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10:71.","journal-title":"Alzheimers Res Ther"},{"key":"1593_CR7","doi-asserted-by":"publisher","first-page":"105937","DOI":"10.1016\/j.nbd.2022.105937","volume":"176","author":"K G\u00f6tze","year":"2023","unstructured":"G\u00f6tze K, Vrillon A, Bouaziz-Amar E, Mouton-Liger F, Hugon J, Martinet M, et al. Plasma neurofilament light chain in memory clinic practice: evidence from a real-life study. Neurobiol Dis. 2023;176:105937.","journal-title":"Neurobiol Dis"},{"key":"1593_CR8","doi-asserted-by":"crossref","unstructured":"Vrillon A, Ashton NJ, Karikari TK, G\u00f6tze K, Cognat E, Dumurgier J et al. Comparison of CSF and plasma NfL and pNfH for Alzheimer\u2019s disease diagnosis: a memory clinic study. J Neurol. 2023.","DOI":"10.21203\/rs.3.rs-3161744\/v1"},{"key":"1593_CR9","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12:3400.","journal-title":"Nat Commun"},{"key":"1593_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/jnnp-2020-323487","volume":"91","author":"A Benussi","year":"2020","unstructured":"Benussi A, Karikari TK, Ashton N, Gazzina S, Premi E, Benussi L, et al. Diagnostic and prognostic value of serum NfL and p-Tau 181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91:960\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1593_CR11","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000011226","volume":"96","author":"I Ill\u00e1n-Gala","year":"2021","unstructured":"Ill\u00e1n-Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, et al. Plasma tau and neurofilament light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology. 2021;96:e671\u201383.","journal-title":"Neurology"},{"key":"1593_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","volume":"93","author":"L Chouliaras","year":"2022","unstructured":"Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;93:651\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1593_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/diagnostics11050754","volume":"11","author":"V Davy","year":"2021","unstructured":"Davy V, Dumurgier J, Fayosse A, Paquet C, Cognat E. Neurofilaments as emerging biomarkers of Neuroaxonal damage to differentiate behavioral Frontotemporal Dementia from Primary Psychiatric disorders: a systematic review. Diagnostics. 2021;11:754.","journal-title":"Diagnostics"},{"key":"1593_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neurobiolaging.2020.05.011","volume":"94","author":"MA Sugarman","year":"2020","unstructured":"Sugarman MA, Zetterberg H, Blennow K, Tripodis Y, McKee AC, Stein TD, et al. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer\u2019s Disease. Neurobiol Aging. 2020;94:60\u201370.","journal-title":"Neurobiol Aging"},{"key":"1593_CR15","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/alz.12324","volume":"17","author":"KJ Bangen","year":"2021","unstructured":"Bangen KJ, Thomas KR, Weigand AJ, Edmonds EC, Clark AL, Solders S, et al. Elevated plasma neurofilament light predicts a faster rate of Cognitive decline over 5 years in participants with objectively-defined subtle cognitive difficulties and MCI. Alzheimers Dement J Alzheimers Assoc. 2021;17:1756\u201362.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"1593_CR16","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","volume":"93","author":"MM Mielke","year":"2019","unstructured":"Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, et al. Plasma and CSF neurofilament light. Neurology. 2019;93:e252\u201360.","journal-title":"Neurology"},{"key":"1593_CR17","first-page":"e12349","volume":"14","author":"S Sapkota","year":"2022","unstructured":"Sapkota S, Erickson K, Harvey D, Tomaszewski-Farias SE, Olichney JM, Johnson DK, et al. Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: mediation with hippocampal volume. Alzheimers Dement Diagn Assess Dis Monit. 2022;14:e12349.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"1593_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/brain\/awad330","volume":"147","author":"S De Meyer","year":"2024","unstructured":"De Meyer S, Blujdea ER, Schaeverbeke J, Reinartz M, Luckett ES, Adamczuk K, et al. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes. Brain J Neurol. 2024;147:936\u201348.","journal-title":"Brain J Neurol"},{"key":"1593_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13195-024-01459-y","volume":"16","author":"HE Dark","year":"2024","unstructured":"Dark HE, An Y, Duggan MR, Joynes C, Davatzikos C, Erus G, et al. Alzheimer\u2019s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline. Alzheimers Res Ther. 2024;16:94.","journal-title":"Alzheimers Res Ther"},{"key":"1593_CR20","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;alz.13859."},{"key":"1593_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"1593_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7:263\u20139.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"1593_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"1593_CR24","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain J Neurol. 2011;134:2456\u201377.","journal-title":"Brain J Neurol"},{"key":"1593_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314.","journal-title":"Neurology"},{"key":"1593_CR26","doi-asserted-by":"publisher","first-page":"eaay1913","DOI":"10.1126\/scitranslmed.aay1913","volume":"12","author":"TF Gendron","year":"2020","unstructured":"Gendron TF, Badi MK, Heckman MG, Jansen-West KR, Vilanilam GK, Johnson PW, et al. Plasma neurofilament light predicts mortality in patients with stroke. Sci Transl Med. 2020;12:eaay1913.","journal-title":"Sci Transl Med"},{"key":"1593_CR27","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1111\/epi.17713","volume":"64","author":"S Akel","year":"2023","unstructured":"Akel S, Asztely F, Banote RK, Axelsson M, Zetterberg H, Zelano J. Neurofilament light, glial fibrillary acidic protein, and tau in a regional epilepsy cohort: high plasma levels are rare but related to seizures. Epilepsia. 2023;64:2690\u2013700.","journal-title":"Epilepsia"},{"key":"1593_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1212\/01.WNL.0000120548.24298.DB","volume":"62","author":"E Barbeau","year":"2004","unstructured":"Barbeau E, Didic M, Tramoni E, Felician O, Joubert S, Sontheimer A, et al. Evaluation of visual recognition memory in MCI patients. Neurology. 2004;62:1317\u201322.","journal-title":"Neurology"},{"key":"1593_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/87565648709540361","volume":"3","author":"E Grober","year":"1987","unstructured":"Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3:13\u201336.","journal-title":"Dev Neuropsychol"},{"key":"1593_CR30","unstructured":"Godefroy O, Grefex. Fonctions ex\u00e9cutives et pathologies neurologiques et psychiatriques, \u00e9valuation en pratique clinique [Internet]. deboeck. 2012 [cited 2023 Oct 24]. https:\/\/www.deboecksuperieur.com\/ouvrage\/9782353270378-fonctions-executives-et-pathologies-neurologiques-et-psychiatriques"},{"key":"1593_CR31","volume-title":"Test De d\u00e9nomination Orale d\u2019images: DO 80","author":"G Deloche","year":"1997","unstructured":"Deloche G, Hannequin D. Test De d\u00e9nomination Orale d\u2019images: DO 80. Paris, France: ECPA, Les \u00e9ditions du Centre de psychologie appliqu\u00e9e; 1997."},{"key":"1593_CR32","first-page":"235","volume":"3","author":"C Merck","year":"2011","unstructured":"Merck C, Charnallet A, Auriacombe S, Belliard S, Hahn-Barma V, Kremin H, et al. La Batterie d\u2019\u00e9valuation des connaissances s\u00e9mantiques du GRECO (BECSGRECO): validation et donn\u00e9es normatives. Rev Neuropsychol. 2011;3:235\u201355.","journal-title":"Rev Neuropsychol"},{"key":"1593_CR33","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","volume":"55","author":"B Dubois","year":"2000","unstructured":"Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55:1621\u20136.","journal-title":"Neurology"},{"key":"1593_CR34","first-page":"206","volume":"30","author":"PA Osterrieth","year":"1944","unstructured":"Osterrieth PA. Le test de copie d\u2019une figure complexe; contribution \u00e0 l\u2019\u00e9tude de la perception et de la m\u00e9moire. [Test of copying a complex figure; contribution to the study of perception and memory]. Arch Psychol. 1944;30:206\u2013356.","journal-title":"Arch Psychol"},{"key":"1593_CR35","doi-asserted-by":"crossref","unstructured":"Wechsler D. Wechsler Adult Intelligence Scale\u2013Fourth Edition. Pearson. 2008.","DOI":"10.1037\/t15169-000"},{"key":"1593_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.neurol.2008.11.016","volume":"165","author":"F Mahieux-Laurent","year":"2009","unstructured":"Mahieux-Laurent F, Fabre C, Galbrun E, Dubrulle A, Moroni C. Groupe de r\u00e9flexion sur les praxies du CMRR ile-de-france Sud. [Validation of a brief screening scale evaluating praxic abilities for use in memory clinics. Evaluation in 419 controls, 127 mild cognitive impairment and 320 demented patients]. Rev Neurol (Paris). 2009;165:560\u20137.","journal-title":"Rev Neurol (Paris)"},{"key":"1593_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"1593_CR38","doi-asserted-by":"publisher","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging [Internet]. [cited 2023 Oct 2]. https:\/\/www.ajronline.org\/doi\/epdf\/https:\/\/doi.org\/10.2214\/ajr.149.2.351","DOI":"10.2214\/ajr.149.2.351"},{"key":"1593_CR39","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in probable Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1593_CR40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3233\/JAD-215096","volume":"85","author":"CR Schubert","year":"2022","unstructured":"Schubert CR, Paulsen AJ, Pinto AA, Merten N, Cruickshanks KJ. Effect of long-term storage on the reliability of blood biomarkers for Alzheimer\u2019s Disease and Neurodegeneration. J Alzheimers Dis JAD. 2022;85:1021\u20139.","journal-title":"J Alzheimers Dis JAD"},{"key":"1593_CR41","first-page":"512","volume":"43","author":"M Poli","year":"2005","unstructured":"Poli M, Benerini Gatta L, Dominici R, Lovati C, Mariani C, Albertini A, et al. Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography - PubMed. Clin Chem Lab Med CCLM. 2005;43:512\u20138.","journal-title":"Clin Chem Lab Med CCLM"},{"key":"1593_CR42","doi-asserted-by":"publisher","first-page":"e12519","DOI":"10.1002\/dad2.12519","volume":"16","author":"TOE de Crom","year":"2024","unstructured":"de Crom TOE, Ghanbari M, Voortman T, Ikram MA. Body composition and plasma total-tau, neurofilament light chain, and amyloid-\u03b2: a population-based study. Alzheimers Dement Amst Neth. 2024;16:e12519.","journal-title":"Alzheimers Dement Amst Neth"},{"key":"1593_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/acn3.50972","volume":"7","author":"A Manouchehrinia","year":"2020","unstructured":"Manouchehrinia A, Piehl F, Hillert J, Kuhle J, Alfredsson L, Olsson T, et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol. 2020;7:139\u201343.","journal-title":"Ann Clin Transl Neurol"},{"key":"1593_CR44","doi-asserted-by":"crossref","unstructured":"Wu J, Xiao Z, Wang M, Wu W, Ma X, Liang X et al. The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: the Shanghai Aging Study. Alzheimers Res Ther [Internet]. 2024 [cited 2024 May 11];16. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10860286\/","DOI":"10.1186\/s13195-024-01401-2"},{"key":"1593_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13195-023-01220-x","volume":"15","author":"M R\u00e9gy","year":"2023","unstructured":"R\u00e9gy M, Dugravot A, Sabia S, Bouaziz-Amar E, Paquet C, Hanseeuw B, et al. Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders. Alzheimers Res Ther. 2023;15:77.","journal-title":"Alzheimers Res Ther"},{"key":"1593_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78:1\u201313.","journal-title":"JAMA Neurol"},{"key":"1593_CR47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13195-021-00944-y","volume":"13","author":"JD Marks","year":"2021","unstructured":"Marks JD, Syrjanen JA, Graff-Radford J, Petersen RC, Machulda MM, Campbell MR, et al. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther. 2021;13:199.","journal-title":"Alzheimers Res Ther"},{"key":"1593_CR48","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3233\/JAD-210092","volume":"82","author":"N Darmanth\u00e9","year":"2021","unstructured":"Darmanth\u00e9 N, Tabatabaei-Jafari H, Cherbuin N, Alzheimer\u2019s Disease Neuroimaging Initiative. Combination of plasma neurofilament light chain and mini-mental state examination score predicts progression from mild cognitive impairment to Alzheimer\u2019s disease within 5 years. J Alzheimers Dis JAD. 2021;82:951\u201364.","journal-title":"J Alzheimers Dis JAD"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01593-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01593-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01593-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T14:06:12Z","timestamp":1729519572000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01593-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01593-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"23 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the participants were provided written information about the opportunity to collect additional blood and CSF samples for further research analyses, in the BioCogBank\u00a9 protocol, in accordance with the Declaration of Helsinki. They also provided informed consent for the anonymous use of their clinical data and the results of their CSF and plasma analyses. The \u201cComit\u00e9 d\u2019Evaluation de l\u2019Ethique des projets de Recherche Biom\u00e9dicale (CEERB) Paris Nord\u201d (Institutional Review Board-IRB 00006477-of HUPNVS, Paris 7 University, AP-HP), has reviewed and approved the research project entitled \u00abClinico-biological database of cognitive disorders\u00bb (Pr Paquet, principal investigator) on May 30, 2016, and the \u201cCommission Nationale Informatique et Libert\u00e9s\u201d (CNIL).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical authorizations and Consent Statement"}},{"value":"KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). CP Serves at scientific international and national advisory boards and\/or as a consultant for Abbvie, Eisai, Roche, Lilly, QWorld, France Alzheimer, Fondation Vaincre Alzheimer, a2MCL association, and Biodimed has given lectures in symposia sponsored by Lilly, Roche, Fujirebio.The other authors report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}